| Ticker |
MXCT
|
| CIK | 0001287098 |
| SIC | 8731 |
| Sector | Services |
| Industry Category | Business Services |
| Industry Group | Services – Research, Development, Testing Labs |
| Address | 9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE, MD, 20850 |
| Website | maxcyte.com |
| Phone | 301-517-5556 |
| CEO | Douglas A. Doerfler |
| Employees | 80 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
MaxCyte, Inc. (MXCT): A Bull Case TheoryWe came across a bullish thesis on MaxCyte, Inc. (MXCT) on Substack by OppCost. In this article, we will summarize the bulls’ thesis on MXCT. MaxCyte, Inc. (MXCT)’s share was trading at $2.355 as of May 9th. MaxCyte, Inc. is a commercial-stage cell-engineering company with a strong strategic position in the rapidly growing cell and gene therapy […] MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ...MaxCyte Inc (MXCT) reports robust operational efficiency and strategic integration, despite facing macroeconomic uncertainties and revenue decline. MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue EstimatesMaxCyte (MXCT) delivered earnings and revenue surprises of 0% and 7.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock? MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 GuidanceROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights Core business revenue of $8.2 million in the first quarter of 2025, an increase of MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p |
